https://mindmedicinelaw.com/briefing/brain-lung-axis-in-neurogenic-pulmonary-edema-new-insights-20260703-18847The Psychedelic Journalen2026-07-04T15:06:19.951417+00:00Brain-Lung Axis in Neurogenic Pulmonary Edema: New Insightsneurogenic pulmonary edema, brain-lung axis, central nervous system injury, sympathetic storm, immune dysregulation, therapeutic interventions, adrenergic pathways, inflammatory pathways, clinical management, neuroscience researchhttps://mindmedicinelaw.com/briefing/evaluating-naturally-derived-psilocybin-a-six-criterion-framework-20260703-18796The Psychedelic Journalen2026-07-04T15:06:03.856948+00:00Evaluating Naturally Derived Psilocybin: A Six-Criterion Frameworknaturally derived psilocybin, therapeutic potential, safety and tolerability, pharmacological uniqueness, dose precision, ecological sustainability, controlled trials, regulatory acceptance, standardization, entourage effectshttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-brain-networks-and-gut-brain-axis-20260703-18848The Psychedelic Journalen2026-07-04T15:05:55.721773+00:00Ketamine's Impact on Brain Networks and Gut-Brain Axisketamine, brain networks, gut-brain axis, psychiatric disorders, FMBFN framework, neural dynamics, depression treatment, chronic social defeat stresshttps://mindmedicinelaw.com/briefing/esketamine-and-antidepressants-for-trd-meta-analysis-insights-20260703-18846The Psychedelic Journalen2026-07-04T15:05:47.506929+00:00Esketamine and Antidepressants for TRD: Meta-Analysis Insightsesketamine, treatment-resistant depression, TRD, antidepressants, systematic review, meta-analysis, adverse events, NMDA receptor, supervised care, clinical trialshttps://mindmedicinelaw.com/briefing/synthetic-psychedelics-and-trd-trials-uncovering-design-flaws-20260703-18587The Psychedelic Journalen2026-07-03T15:03:45.813507+00:00Synthetic Psychedelics and TRD Trials: Uncovering Design Flawssynthetic psychedelics, treatment-resistant depression, TRD trial design, clinical trial limitations, psychedelic research, depression treatment, psychedelic effects, trial methodologieshttps://mindmedicinelaw.com/briefing/fmri-neurofeedback-mood-effects-subjective-success-over-training-20260702-18850The Psychedelic Journalen2026-07-04T15:06:27.816697+00:00fMRI Neurofeedback Mood Effects: Subjective Success Over TrainingfMRI neurofeedback, mood regulation, subjective success, brain activity, psychiatric treatment, clinical trials, neurofeedback efficacy, placebo effect, mental health, neuroscience researchhttps://mindmedicinelaw.com/briefing/variability-in-psilocybe-cubensis-tryptamine-profiles-challenges-standardization-20260702-18833The Psychedelic Journalen2026-07-04T15:06:10.739952+00:00Variability in Psilocybe cubensis Tryptamine Profiles Challenges Standardizationpsilocybe cubensis, tryptamine variability, psilocybin standardization, psychedelic research, clinical applications, biochemical diversity, strain selection, chemical profiling, therapeutic dosing, psychedelic therapieshttps://mindmedicinelaw.com/briefing/im-ketamine-a-cost-effective-alternative-for-trd-20260702-18686The Psychedelic Journalen2026-07-03T22:04:34.855184+00:00IM Ketamine: A Cost-Effective Alternative for TRDintramuscular ketamine, intranasal esketamine, treatment-resistant depression, cost-effective treatment, psychiatric care access, real-world evidence, healthcare policy, clinical practice, depression treatment, veterans affairs studyhttps://mindmedicinelaw.com/briefing/fda-dea-consider-rescheduling-psychedelics-in-2026-20260702-18632The Psychedelic Journalen2026-07-03T22:04:25.802233+00:00FDA & DEA Consider Rescheduling Psychedelics in 2026psychedelic rescheduling, FDA, DEA, psilocybin, MDMA, LSD, DMT, clinical trials, Controlled Substances Act, mental health treatmenthttps://mindmedicinelaw.com/briefing/ai-in-psychedelic-trials-navigating-legal-risks-20260702-18589The Psychedelic Journalen2026-07-03T15:03:55.210818+00:00AI in Psychedelic Trials: Navigating Legal RisksAI in clinical trials, psychedelic research, legal risks, data privacy, trial participant selection, GDPR compliance, HIPAA regulations, AI bias, ethical standards, AI transparencyhttps://mindmedicinelaw.com/briefing/psilocybin-mushrooms-cultural-and-therapeutic-roles-reviewed-20260701-18638The Psychedelic Journalen2026-07-04T22:05:41.017439+00:00Psilocybin Mushrooms: Cultural and Therapeutic Roles Reviewedpsilocybin, hallucinogenic mushrooms, mental health treatment, cultural significance, obsessive-compulsive disorder, depression, ethnobotanical uses, recreational use, therapeutic potential, cultural contexthttps://mindmedicinelaw.com/briefing/magnesium-s-role-in-enhancing-morphine-efficacy-in-diabetic-rats-20260701-18688The Psychedelic Journalen2026-07-04T22:05:32.960823+00:00Magnesium's Role in Enhancing Morphine Efficacy in Diabetic Ratsmagnesium ions, morphine efficacy, neuropathic pain, diabetic rats, pain management, NMDAR antagonists, opioid analgesia, clinical trials, neurotrophic factors, public healthhttps://mindmedicinelaw.com/briefing/postoperative-pain-management-in-cancer-new-insights-20260701-18692The Psychedelic Journalen2026-07-04T22:05:22.473515+00:00Postoperative Pain Management in Cancer: New Insightspostoperative pain, cancer patients, behavioral disorders, opioid sparing, multimodal analgesia, personalized medicine, psycho-emotional factors, pain management, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/esketamine-reduces-ciprofol-rate-in-endoscopy-trial-insights-20260701-18855The Psychedelic Journalen2026-07-04T22:05:14.859624+00:00Esketamine Reduces Ciprofol Rate in Endoscopy: Trial Insightsesketamine, ciprofol, gastrointestinal endoscopy, sedation protocols, hemodynamic stability, neuropsychiatric symptoms, clinical trials, hypotension, procedural sedation, adverse eventshttps://mindmedicinelaw.com/briefing/intranasal-esketamine-and-itbs-for-severe-depression-a-case-study-20260701-18858The Psychedelic Journalen2026-07-04T22:05:07.360323+00:00Intranasal Esketamine and iTBS for Severe Depression: A Case Studyintranasal esketamine, theta-burst stimulation, treatment-resistant depression, suicidal ideation, psychiatric emergency, neuroscience, clinical trials, mental health treatment, depression therapy, innovative treatmentshttps://mindmedicinelaw.com/briefing/tms-trial-for-anorexia-nervosa-promising-results-in-body-perception-20260701-18693The Psychedelic Journalen2026-07-03T22:05:16.611009+00:00TMS Trial for Anorexia Nervosa: Promising Results in Body Perceptionanorexia nervosa, theta burst TMS, extrastriate body area, body perception, neuromodulation, precision psychiatry, clinical trial, psychiatric treatment, neuroscience, behavioral traininghttps://mindmedicinelaw.com/briefing/psilocybin-and-alcohol-co-use-mental-health-implications-20260701-18295The Psychedelic Journalen2026-07-03T22:05:02.847859+00:00Psilocybin and Alcohol Co-Use: Mental Health Implicationspsilocybin, alcohol co-use, depressive symptoms, mental health, observational study, psychedelic research, clinical trials, public health, self-reported data, longitudinal studieshttps://mindmedicinelaw.com/briefing/psilocybin-and-5-meo-dmt-bridging-tradition-and-therapy-20260701-18296The Psychedelic Journalen2026-07-03T22:04:52.897689+00:00Psilocybin and 5-MeO-DMT: Bridging Tradition and Therapypsilocybin, 5-MeO-DMT, mental health, neuroplasticity, serotonin receptors, clinical trials, traditional use, psychedelic therapy, FDA, EMAhttps://mindmedicinelaw.com/briefing/ketamine-misuse-treatment-fragmented-approaches-highlight-need-for-standardizati-20260701-18690The Psychedelic Journalen2026-07-03T22:04:44.917850+00:00Ketamine Misuse Treatment: Fragmented Approaches Highlight Need for Standardizationketamine misuse, treatment approaches, systematic review, multidisciplinary strategies, psychiatric complications, somatic complications, standardized protocols, clinical evidence, relapse rates, pharmacological treatmentshttps://mindmedicinelaw.com/briefing/ketamine-misuse-interventions-clinical-and-policy-implications-20260701-18577The Psychedelic Journalen2026-07-03T15:04:08.357739+00:00Ketamine Misuse Interventions: Clinical and Policy Implicationsketamine misuse, medical interventions, systematic review, therapeutic use, policy implications, treatment protocols, public health, clinical trials, neuroscience, substance misusehttps://mindmedicinelaw.com/briefing/incentive-misalignment-in-psychedelic-medicine-economic-challenges-20260630-18806The Psychedelic Journalen2026-07-04T22:05:50.483788+00:00Incentive Misalignment in Psychedelic Medicine: Economic Challengesincentive misalignment, psychedelic medicine, healthcare economics, patient autonomy, healthspan-oriented care, reimbursement models, pharmaceutical influence, evidence-based carehttps://mindmedicinelaw.com/briefing/esketamine-biomarker-study-in-mdd-a-new-frontier-in-treatment-20260630-18358The Psychedelic Journalen2026-07-03T15:03:28.575218+00:00Esketamine Biomarker Study in MDD: A New Frontier in Treatmentesketamine, major depressive disorder, biomarkers, treatment resistance, multi-omic, personalized medicine, clinical trials, neuroscience, EU Psych-STRATA, machine learninghttps://mindmedicinelaw.com/briefing/mdma-and-psilocybin-therapy-rules-relaxed-in-2026-20260629-18588The Psychedelic Journalen2026-07-03T15:03:18.790231+00:00MDMA and Psilocybin Therapy Rules Relaxed in 2026MDMA therapy, psilocybin therapy, regulatory changes, psychedelic research, clinical trials, mental health treatment, FDA, EMA, Schedule I substances, psychedelic therapieshttps://mindmedicinelaw.com/briefing/ketamine-s-adverse-effects-in-emergency-medicine-20260628-18347The Psychedelic Journalen2026-07-03T15:03:36.081028+00:00Ketamine's Adverse Effects in Emergency Medicineketamine adverse effects, emergency medicine, psycho-perceptual effects, ketamine-induced cystitis, ketamine-associated cholangiopathy, ketamine use disorder, recreational ketamine use, emergency physicians, patient care, clinical management